Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼ö¼ú ÈÄ ±¹¼Ò Àç¹ßÇÑ ÀڱðæºÎ¾Ï¿¡¼­ÀÇ ¹æ»ç¼±Ä¡·á ¼ºÀû Radiotherapy Results for Recurrent Uterine Cervical Cancer after Surgery

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 1999³â 17±Ç 3È£ p.217 ~ 222
¼Ò¼Ó »ó¼¼Á¤º¸
À¯¹Ì·É/Mi Ryeong Ryu °èö½Â/°­±â¹®/±è¿¬½Ç/Á¤¼ö¹Ì/³²±Ã¼ºÀº/À±¼¼Ã¶/Chul Seung Kay/Ki Moon Kang/Yeon Shil Kim/Su Mi Chung/Sung Eun Namkoong/Sei Chul Yoon

Abstract

¸ñ Àû : ±ÙÄ¡Àû ¼ö¼ú ÈÄ ±¹¼Ò Àç¹ßÇÑ ÀڱðæºÎ¾Ï Ä¡·á¿¡ À־ ¹æ»ç¼±Ä¡·áÀÇ ¿ªÇÒ ¹× Ä¡
·á°á°ú¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀÚµéÀ» ºÐ¼®ÇÏ°íÀÚ º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 1983³â 10¿ùºÎÅÍ 1996³â 7¿ù±îÁö °¡Å縯´ëÇб³ °­³²¼º¸ðº´¿ø Ä¡·á ¹æ»ç¼±
°ú¿¡¼­ FIGOº´±â ¥°, ¥± ÀڱðæºÎ¾ÏÀÇ ±ÙÄ¡Àû ¼ö¼ú ÈÄ ±¹¼Ò Àç¹ßÇÑ È¯ÀÚ Áß ¹æ»ç¼±Ä¡·á¸¦
¹Þ¾Ò´ø 53¸íÀ» ´ë»óÀ¸·Î Ä¡·á°á°ú¿¡ ´ëÇÑ ÈÄÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù. ȯÀÚÀÇ ¿¬·ÉÀº 33¼¼¿¡
¼­ 69¼¼ »çÀÌ(Áß¾Ó°ª 53¼¼)¿´À¸¸ç, º´¸®Á¶Á÷ÇÐÀû ºÐ·ù·Î´Â ÆíÆò»óÇǾÏÀÌ 45¸í(84.9%), ¼±¾Ï
ÀÌ 7¸í(13.2%), ÆíÆò»óÇǼ±¾ÏÀÌ 1¸í(1.9%)À̾ú´Ù. ¼ö¼ú ÈÄ Àç¹ß±îÁöÀÇ ±â°£Àº 2 °³¿ù¿¡¼­ 25
³â »çÀÌ·Î Æò±Õ 34.4 °³¿ùÀ̾ú´Ù. Àç¹ßÇÑ º´¼ÒÀÇ À§Ä¡¿¡ µû¶ó¼­ Áú ÀýÁ¦´Ü(vaginal stump)ÀÌ
41¸í(77.4%), °ñ¹Ý ¿Üº®(pelvic slue wall)ÀÌ 12¸í(22.6%)À̾ú°í, Àç¹ßÇÑ º´¼Ò¸¦ Å©±â¿¡ µû¶ó
³ª´©¾úÀ» ¶§ 3§¯ ÀÌÇÏÀÎ °æ¿ì°¡ 43¸í(81.1%), 3§¯º¸´Ù Å« °æ¿ì°¡ 10¸í(18.9%)À̾ú´Ù.
¹æ»ç¼±Ä¡·á´Â ´ëºÎºÐ ȯÀÚ¿¡¼­ Àü°ñ¹Ý¿¡ ¿ÜºÎ ¹æ»ç¼±Ä¡·á¸¦ ÇÏ·ç 1.8 §íÀÇ ¾çÀ¸·Î ÁÖ 5ȸ
¾¿ Ä¡·áÇÏ¿© 46.8¡­50.4§í±îÁö Ä¡·áÇÑ ÈÄ, 18¸í(34%)¿¡¼­´Â º´¼Ò ºÎÀ§¿¡ ¿ÜºÎ ¹æ»ç¼±Ä¡·á¸¦,
24¸í(45.3%)ÀÇ È¯ÀÚ¿¡¼­´Â °­³»±ÙÁ¢Ä¡·á¸¦ °¢°¢ Ãß°¡ÇÏ¿© Ãѹæ»ç¼±·® 46.8¡­111 §í(Áß¾Ó°ª
70.2 §í)±îÁö Ä¡·áÇÏ¿´´Ù. ÃßÀûÁ¶»ç ±â°£Àº 2 °³¿ù¿¡¼­ 153 °³¿ù »çÀÌ(Áß¾Ó°ª 35 °³¿ù)¿´´Ù.
°á °ú : ¹æ»ç¼±Ä¡·á ÈÄ Ãʱâ°üÇØÀ²Àº 66% (35/53)À̾ú°í, ÀÌ Áß 6¸í(17.1%)¿¡¼­ ¹æ»ç¼±Ä¡
·á ÈÄ 7 °³¿ù¿¡¼­ 116 °³¿ù »çÀÌ(Æò±Õ 47.7 °³¿ù)¿¡ ´Ù½Ã ±¹¼Ò Àç¹ßÇÏ¿© Àüü ȯÀÚÀÇ ±¹¼Ò
Àç¹ßÀ²Àº 45.3%¿´´Ù. Àüü ȯÀÚÀÇ 5³â »ýÁ¸À²Àº 78.9%ÀÌ¿´À¸¸ç, ¿ø°Ý ÀüÀÌÀ²Àº 10% (5/50)
·Î ¹ß»ý ºÎÀ§º°·Î´Â Æó 2¸í, ³ú 1¸í, ¿ø°Ý ÀÓÆÄÀý 2¸íÀ̾ú´Ù. »ýÁ¸À²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀÚ
·Î´Â ¼ö¼ú ÈÄ Àç¹ß±îÁöÀÇ ±â°£(p=0.0055), Àç¹ß º´¼ÒÀÇ Å©±â(p=0.0039), ¹æ»ç¼±Ä¡·á¿¡ ´ëÇÑ
Ãʱâ¹ÝÀÀ À¯¹«(p=0.0428) µîÀ¸·Î ºÐ¼®µÇ¾úÀ¸¸ç, ±× ¿Ü¿¡ Ãʱ⠺´±â, ¿¬·É, Á¶Á÷ÇÐÀû À¯Çü, Àç
¹ßº´¼ÒÀÇ À§Ä¡, ¹æ»ç¼± Á¶»ç·®, ¾à¹°Ä¡·á À¯¹« µîÀº ¿µÇâÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù(p>0.05).
¹æ»ç¼±Ä¡·áÀÇ ÇÕº´ÁõÀº 10¸í(20%)¿¡¼­ ¹ß»ýÇÏ¿´À¸³ª, ´ëºÎºÐ °æ¹ÌÇϰųª ÁߵÀÇ ÇϺÎ
À§Àå°ü ¶Ç´Â ºñ´¢±â°è, ÇǺΠÇÕº´ÁõÀ̾ú°í, ÇѸíÀÌ °­³» ¹æ»ç¼±Ä¡·á Á÷ÈÄ ÆóÀü»öÁõÀ¸·Î »ç¸Á
ÇÏ¿´´Ù.
°á °ú : ±ÙÄ¡Àû ¼ö¼ú ÈÄ ±¹¼Ò Àç¹ßÇÑ ÀڱðæºÎ¾Ï ȯÀÚ¿¡¼­ ¹æ»ç¼±Ä¡·á´Â ¸Å¿ì È¿°úÀûÀ̸ç,
¼ö¼ú ÈÄ Àç¹ß±îÁöÀÇ ±â°£, Àç¹ß º´¼ÒÀÇ Å©±â, ¹æ»ç¼±Ä¡·á¿¡ ´ëÇÑ Ãʱâ¹ÝÀÀ µîÀÌ ¿¹ÈÄ¿¡ ¿µÇâ
À» ¹ÌÄ¡´Â ÀÎÀÚ·Î ³ªÅ¸³µ´Ù.

Purpose : To evaluate prognostic factors and survival rates of the patients who
received radiation therapy for locally recurrent uterine cervical cancer after curative
surgery.
Materials and Methods : Between October 1983 and July 1996, fifty three patients who
received radiation therapy for locally recurrent cervical cancer after curative surgery at
the Department of Therapeutic Radiology, Kangnam St. Mary's Hospital, The Catholic
University of Korea were analysed retrospectively. Age at diagnosis ranged from 33 to
69 years (median 53 years). Pathological analysis showed that forty five (84.9%) patients
had squamous cell carcinoma, seven (13.2%) patients had adenocarcinoma, and one
(1.9%) patient had adenosquamous cell carcinoma. The interval between hysterectomy
and tumor recurrence ranged from 2 months to 25 years (mean 34.4 months). The
recurrent sites were vaginal stump in 41 patients (77.4%) and pelvic side wall in 12
patients (22.6%). Recurrent tumor size was deviled into two groups : less than 3 §¯ in
43 patients (81.1%) and more than 3 cm in 10 patients (18.9%). External beam
irradiation of whole pelvis was done first up to 46.8 §í to 50.4 §í in 5 weeks to 6
weeks, followed by either external beam boost to the recurrent site in 18 patients (34%)
or intracavitary irradiation in 24 patients (45.3%). Total dose of radiation ranged from
46.8 §í to 111 §í (median 70.2 §í). Follow up period ranged from 2 to 153 months with
a median of 35 months.
Results : Overall response rate was 66% (35/53). Among them, six patients (17.1%)
relapsed between 7 months and 116 months after radiation therapy (mean 47.7 months).
Therefore overall recurrence rate was 45.3%. Overall five-year actuarial survival rate
was 78.9% and distant failure rate was 10% (5/50). The significant prognostic factors
affecting survival rate were interval between primary surgery and tumor recurrence
(p=0.0055), recurrent tumor size (p=0.0039), and initial response to radiation therapy
(p=0.0428). Complications were observed in 10 (20%) patients, which included mild to
moderate lower gastrointestinal, genitourinary, or skin manifestations. One patient died of
pulmonary embolism just after intracavitary irradiation.
Conclusion : Radiation therapy is the effective treatment for the patients with locally
recurrent cervical cancer after curative surgery. These results suggest that interval
between primary surgery and tumor recurrence, recurrent tumor size, and initial
response to radiation therapy were significant prognostic factors for recurrent cervical
cancer.

Å°¿öµå

±¹¼Ò Àç¹ß ÀڱðæºÎ¾Ï@¹æ»ç¼±Ä¡·á; ¿¹ÈÄ ÀÎÀÚ; Local recurrence; Cervical cancer; Radiation therapy; Prognostic factors;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS